Global Brigatinib Market Outlook
Revenue, 2024
$588M
Forecast, 2034
$1.25B
CAGR, 2025 - 2034
7.8%
The Brigatinib industry revenue is expected to be around $634.4 million in 2025 and expected to showcase growth with 7.8% CAGR between 2025 and 2034. The robust growth trajectory of Brigatinib is underpinned by several key factors. The increasing prevalence of non-small cell lung cancer , for which Brigatinib is a proven treatment, is a significant driver of this growth. Additionally, the ongoing advancements in cancer therapeutics and a heightened focus on personalized medicine are also contributing to the markets expansion. As a targeted therapy, Brigatinib is an integral part of this evolving landscape, demonstrating its ongoing relevance in the oncology sector.
Brigatinib, also known by its brand name Alunbrig, functions as an anaplastic lymphoma kinase inhibitor which doctors use to treat patients with metastatic NSCLC. The drug works by blocking the abnormal protein that tells cancer cells to multiply which results in tumor growth inhibition. The increasing popularity of targeted therapies and precision medicine has driven up the demand for Brigatinib.
Market Key Insights
- The Brigatinib market is projected to grow from $588.5 million in 2024 to $1.25 billion in 2034. This represents a CAGR of 7.8%, reflecting rising demand across Oncology Treatment, Personalized Medicine and Clinical Trials.
- The market exhibits an oligopolistic structure with only 6 prominent players, with Takeda Pharmaceutical Company Limited and Dr. Reddy’s Laboratories commanding the largest shares.
- U.S. and Germany are the top markets within the Brigatinib market and are expected to observe the growth CAGR of 5.1% to 7.5% between 2024 and 2030.
- Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 9.0% to 10.8%.
- Slow adoption of Adoption of Precision Medicine transition within key players in Brigatinib market is creating a revenue window for adjacent and alternate markets like Alectinib and Crizotinib to improve its use-case penetration in and applications and expected to capture $41 million revenue from existing Brigatinib market.
- The Brigatinib market is set to add $659 million between 2024 and 2034, with manufacturer targeting Retail Pharmacies & Online Pharmacies Distribution Channels projected to gain a larger market share.
- With Increasing incidence of non-small cell lung cancer, and Technological advancements in drug development, Brigatinib market to expand 112% between 2024 and 2034.
Opportunities in the Brigatinib
The dynamic nature of the pharmaceutical industry necessitates continuous research and development. Strategic collaborations between Brigatinib manufacturers and research institutions could also lead to the discovery of new applications for Brigatinib, potentially expanding its therapeutic scope and market reach.
Growth Opportunities in North America and Asia-Pacific
North America, a dominant player in the Brigatinib market, is driven by advanced healthcare infrastructure and high cancer prevalence. The regions market is characterized by intense competition, with leading pharmaceutical companies investing heavily in research and development. The FDAs approval of Brigatinib for treating non-small cell lung cancer has opened new avenues for growth, making the region a hotspot for Brigatinib. However, the high cost of treatment remains a significant challenge, necessitating strategic pricing models and patient assistance programs.
In the Asia-Pacific region, the Brigatinib market is witnessing rapid growth due to increasing healthcare expenditure and rising cancer incidence. Countries like China and India, with their burgeoning middle-class population and improving healthcare access, are emerging as key demand centers for Brigatinib. The market here is marked by the presence of both international and local players, fostering a competitive landscape. Despite the promising growth, regulatory hurdles and patent issues pose potential roadblocks in the region. The success in this market hinges on effective collaboration with local partners and tailoring strategies to suit regional needs.
Market Dynamics and Supply Chain
01
Driver: Increasing Incidence of Non-Small Cell Lung Cancer, and Growing Adoption of Targeted Therapies
The rising incidence of non-small cell lung cancer globally is also a significant market for Brigatinib. As a second-generation ALK inhibitor, Brigatinib has also shown promising results in treating patients with ALK-positive NSCLC, especially those who have also developed resistance to first-generation inhibitors. This increasing prevalence of NSCLC propels the demand for effective treatments, thereby driving the growth of Brigatinib in the market. The growing adoption of targeted therapies in oncology is also another significant for the Brigatinib market. As a targeted therapy, Brigatinib works by specifically identifying and attacking cancer cells, thereby reducing damage to healthy cells. This precision makes Brigatinib an attractive option for healthcare providers and patients, further driving its market growth.
The pharmaceutical industry's technological advancements have also led to the development of more effective and targeted therapies like Brigatinib. These advancements in drug development technology enable the production of drugs with higher efficacy, fewer side effects, and improved patient compliance, thereby driving the demand for Brigatinib.
02
Restraint: High Treatment Costs
The high cost of Brigatinib treatment is a significant market.This oncology drug, used in the treatment of non-small cell lung cancer, is often beyond the financial reach of many patients. High treatment costs can deter potential users, negatively impacting market demand.
03
Opportunity: Expanding into Untapped Markets and Technological Innovations in Drug Delivery
The global market for Brigatinib, a potent ALK inhibitor, is expected to witness significant growth, particularly in developing countries. These regions, with their growing healthcare infrastructure and increasing awareness of lung cancer treatments, present a promising for Brigatinib. By focusing on these untapped markets, manufacturers can leverage the rising demand and enhance their global footprint.
The application of Brigatinib in the treatment of non-small cell lung cancer has been well-established. However, the potential for technological innovations in drug delivery systems, such as nanoparticle-based delivery, could further enhance the efficacy and safety of Brigatinib, thereby driving its market growth.
04
Challenge: Regulatory Hurdles
The stringent regulatory landscape for drug approval also presents a challenge for the Brigatinib market. The complex and time-consuming process of obtaining regulatory approval often delays market entry, impacting the market dynamics and growth.
Supply Chain Landscape
1
Raw Material Procurement
BASF SEDowDuPont Inc
2
API Production
Pfizer Inc.Novartis AG
3
Drug Formulation & Packaging
Takeda Pharmaceutical Company LimitedRoche Holding AG
4
Distribution & Retail
Walgreens Boots AllianceCVS Health Corporation
1
Raw Material Procurement
BASF SEDowDuPont Inc
2
API Production
Pfizer Inc.Novartis AG
3
Drug Formulation & Packaging
Takeda Pharmaceutical Company LimitedRoche Holding AG
4
Distribution & Retail
Walgreens Boots AllianceCVS Health Corporation
Use Cases of Brigatinib in Oncology Treatment & Personalized Medicine
Oncology Treatment : Brigatinib is widely used as a potent inhibitor in the treatment of non-small cell lung cancer. It specifically targets ALK, a gene that when mutated or altered, aids in the development of cancer. While crizotinib has been a standard first-line therapy for ALK-positive NSCLC, Brigatinib offers the added advantage of overcoming resistance to crizotinib and other initial treatments, making it a preferred choice for patients with advanced disease. Top players in this market include ARIAD Pharmaceuticals, a company renowned for its innovative cancer therapies and strong market position.
Clinical Trials : Brigatinib is frequently used in clinical trials to explore its efficacy and safety in treating others of cancer. The drugs ability to inhibit multiple tyrosine kinases makes it a promising candidate for broad-spectrum cancer treatment. Major pharmaceutical companies like Novartis are leading the way in these trials, leveraging their extensive research capabilities and market influence.
Personalized Medicine : The use of Brigatinib in personalized medicine is gaining traction. By targeting specific genetic mutations, Brigatinib allows for more tailored treatment plans, increasing the likelihood of positive patient outcomes. Companies like Genentech are at the forefront of this application, capitalizing on their expertise in genetic research and strong market presence.
Recent Developments
Alunbrig, an anaplastic lymphoma kinase inhibitor, has been making significant strides in the pharmaceutical industry. Recent market developments indicate a growing demand for this potent medication, particularly in the treatment of non-small cell lung cancer.This trend is largely driven by the increasing prevalence of NSCLC and the demonstrated efficacy of Brigatinib in managing this condition. The pharmaceutical landscape is witnessing a surge in the adoption of targeted therapies like Brigatinib.
December 2024 : Pharmaceutical giant Pfizer announced plans to expand its Brigatinib production facilities to meet the growing global demand
October 2024 : Brigatinib received approval from the European Medicines Agency for the treatment of metastatic non-small cell lung cancer
August 2024 : Novartis launched its own version of Brigatinib, further intensifying the competitive landscape in the Brigatinib market.
Impact of Industry Transitions on the Brigatinib Market
As a core segment of the Pharmaceutical industry,
the Brigatinib market develops in line with broader industry shifts.
Over recent years, transitions such as Adoption of Precision Medicine and Advancements in Clinical Trials have redefined priorities
across the Pharmaceutical sector,
influencing how the Brigatinib market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Adoption of Precision Medicine
The pharmaceutical industry has been witnessing a significant transition towards precision medicine, which is fundamentally reshaping the way treatments like Brigatinib are developed and administered. Precision medicine allows for a more personalized approach to patient care, taking into account individual genetic makeup, lifestyle, and environment. The impact of this transition is evident in the increasing number of targeted therapies like Brigatinib, which is specifically designed to inhibit certain proteins in cancer cells. This tailored approach improves treatment efficacy and reduces side effects, ultimately enhancing patient outcomes and quality of life. This industry transition is expected to add $41 million in the industry revenue between 2024 and 2030.
02
Advancements in Clinical Trials
The development and approval of Brigatinib have been significantly influenced by advancements in clinical trial methodologies. The traditional model of clinical trials has evolved to incorporate more sophisticated designs and statistical methods, enabling more efficient and accurate evaluation of drug efficacy and safety. For instance, Brigatinibs approval was expedited due to the use of innovative trial designs that allowed for quicker data collection and analysis. This transition has not only accelerated the drug approval process but also facilitated the entry of more effective treatments into the market, thereby improving patient access to life-saving therapies.